Motegrity (prucalopride) Disease Interactions
There are 4 disease interactions with Motegrity (prucalopride):
Prucalopride (applies to Motegrity) intestinal inflammation
Major Potential Hazard, Moderate plausibility. Applicable conditions: Inflammatory Bowel Disease
The use of prucalopride is contraindicated in patients with severe inflammatory conditions of the intestinal tract such as Crohn's disease, ulcerative colitis, and toxic megacolon/megarectum.
Prucalopride (applies to Motegrity) intestinal perforation
Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Perforation, Gastrointestinal Obstruction
The use of prucalopride is contraindicated in patients with obstructive ileus, and intestinal perforation or obstruction due to structural or functional disorder of the gut wall.
Prucalopride (applies to Motegrity) renal dysfunction
Major Potential Hazard, Moderate plausibility.
Prucalopride is known to be substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. No dosage adjustment is required for patients with mild and moderate renal impairment. A decreased dosage is recommended in patients with severe renal impairment. Avoid the use of prucalopride in patients with end-stage renal disease requiring dialysis.
Prucalopride (applies to Motegrity) depression
Moderate Potential Hazard, Moderate plausibility.
Suicides, suicide attempts, and suicidal ideation have been reported with the use of prucalopride. It is recommended to monitor all patients for persistent worsening of depression or the emergence of suicidal thoughts and behaviors. Patients should discontinue prucalopride immediately if they experience any of these symptoms.
Motegrity (prucalopride) drug interactions
There are 95 drug interactions with Motegrity (prucalopride)
More about Motegrity (prucalopride)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- 32 Reviews
- Drug class: serotoninergic neuroenteric modulators
- FDA Approval History
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.